Submit Feedback
Recent searches
    Trending searches
    AbbVie
    +
    Revenue breakdown by Products & Services
    Revenue breakdown by Geography

    AbbVie's Revenue by Segment

    In fiscal year , AbbVie's revenue by segment (products & services) are as follows:


    Learn more about AbbVie’s Revenue by Geography

    Check out competitors to AbbVie in a side-by-side comparison.

    Explore additional financial metrics for AbbVie.

    Continue reading...

    The above chart shows AbbVie's revenue percentage share by segment (products and services).

    In fiscal year 2022, AbbVie's revenue by segment is as follows:

    • Alphagan/Combigan generated $346.00M in revenue, representing 0.62% of its total revenue.
    • Botox Cosmetic generated $2.62B in revenue, representing 4.67% of its total revenue.
    • Botox Therapeutic generated $2.72B in revenue, representing 4.86% of its total revenue.
    • Duodopa generated $458.00M in revenue, representing 0.82% of its total revenue.
    • H U M I R A generated $21.24B in revenue, representing 37.97% of its total revenue.
    • Imbruvica generated $4.57B in revenue, representing 8.17% of its total revenue.
    • Juvederm Collection generated $1.43B in revenue, representing 2.55% of its total revenue.
    • Linzess/Constella generated $1.04B in revenue, representing 1.85% of its total revenue.
    • Lumigan/Ganfort generated $514.00M in revenue, representing 0.92% of its total revenue.
    • MAVYRET generated $1.54B in revenue, representing 2.75% of its total revenue.
    • Other Aesthetics generated $1.29B in revenue, representing 2.31% of its total revenue.
    • Other Eye Care generated $1.18B in revenue, representing 2.1% of its total revenue.
    • Other Neuroscience generated $475.00M in revenue, representing 0.85% of its total revenue.
    • Other Products generated $4.14B in revenue, representing 7.4% of its total revenue.
    • Restasis generated $666.00M in revenue, representing 1.19% of its total revenue.
    • RINVOQ generated $2.52B in revenue, representing 4.51% of its total revenue.
    • SKYRIZI generated $5.17B in revenue, representing 9.23% of its total revenue.
    • VENCLEXTA generated $2.01B in revenue, representing 3.59% of its total revenue.
    • Vraylar generated $2.04B in revenue, representing 3.64% of its total revenue.

    The biggest segment for AbbVie is the H U M I R A, which represents 37.97% of its total revenue.
    The smallest segment for AbbVie is the Alphagan/Combigan, which represents 0.62% of its total revenue.

    The above chart shows AbbVie's revenue percentage share by segment (products and services).

    In fiscal year 2023, AbbVie's revenue by segment is as follows:

    • Alphagan/Combigan generated $272.00M in revenue, representing 0.51% of its total revenue.
    • Botox Cosmetic generated $2.68B in revenue, representing 5.06% of its total revenue.
    • Botox Therapeutic generated $2.99B in revenue, representing 5.64% of its total revenue.
    • Duodopa generated $468.00M in revenue, representing 0.88% of its total revenue.
    • H U M I R A generated $14.40B in revenue, representing 27.17% of its total revenue.
    • Imbruvica generated $3.60B in revenue, representing 6.78% of its total revenue.
    • Juvederm Collection generated $1.38B in revenue, representing 2.6% of its total revenue.
    • Linzess/Constella generated $1.11B in revenue, representing 2.09% of its total revenue.
    • Lumigan/Ganfort generated $432.00M in revenue, representing 0.81% of its total revenue.
    • MAVYRET generated $1.43B in revenue, representing 2.7% of its total revenue.
    • Other Aesthetics generated $1.23B in revenue, representing 2.33% of its total revenue.
    • Other Eye Care generated $803.00M in revenue, representing 1.51% of its total revenue.
    • Other Neuroscience generated $276.00M in revenue, representing 0.52% of its total revenue.
    • Other Products generated $3.04B in revenue, representing 5.72% of its total revenue.
    • Ozurdex generated $472.00M in revenue, representing 0.89% of its total revenue.
    • Qulipta generated $408.00M in revenue, representing 0.77% of its total revenue.
    • Restasis generated $436.00M in revenue, representing 0.82% of its total revenue.
    • RINVOQ generated $3.97B in revenue, representing 7.49% of its total revenue.
    • SKYRIZI generated $7.76B in revenue, representing 14.64% of its total revenue.
    • Ubrelvy generated $815.00M in revenue, representing 1.54% of its total revenue.
    • VENCLEXTA generated $2.29B in revenue, representing 4.32% of its total revenue.
    • Vraylar generated $2.76B in revenue, representing 5.2% of its total revenue.

    The biggest segment for AbbVie is the H U M I R A, which represents 27.17% of its total revenue.
    The smallest segment for AbbVie is the Alphagan/Combigan, which represents 0.51% of its total revenue.
    Continue reading...

    Summary Table

    Products & Services (Percent Share) 2022 2023 2024
    Other Products 7.4% 5.72% -
    Botox Cosmetic 4.67% 5.06% -
    Juvederm Collection 2.55% 2.6% -
    Other Aesthetics 2.31% 2.33% -
    Alphagan/Combigan 0.62% 0.51% -
    Lumigan/Ganfort 0.92% 0.81% -
    Other Eye Care 2.1% 1.51% -
    Restasis 1.19% 0.82% -
    Imbruvica 8.17% 6.78% -
    VENCLEXTA 3.59% 4.32% -
    H U M I R A 37.97% 27.17% -
    RINVOQ 4.51% 7.49% -
    SKYRIZI 9.23% 14.64% -
    Botox Therapeutic 4.86% 5.64% -
    Duodopa 0.82% 0.88% -
    Other Neuroscience 0.85% 0.52% -
    Vraylar 3.64% 5.2% -
    Linzess/Constella 1.85% 2.09% -
    MAVYRET 2.75% 2.7% -
    Ozurdex - 0.89% -
    Qulipta - 0.77% -
    Ubrelvy - 1.54% -
    Total Revenue 100% 100% 100%

    The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Alphagan/Combigan revenue decreased -100% ($272.00M) from $272.00M (in 2023) to $0.00 (in 2024).
  • Botox Cosmetic revenue decreased -100% ($2.68B) from $2.68B (in 2023) to $0.00 (in 2024).
  • Botox Therapeutic revenue decreased -100% ($2.99B) from $2.99B (in 2023) to $0.00 (in 2024).
  • Duodopa revenue decreased -100% ($468.00M) from $468.00M (in 2023) to $0.00 (in 2024).
  • H U M I R A revenue decreased -100% ($14.40B) from $14.40B (in 2023) to $0.00 (in 2024).
  • Imbruvica revenue decreased -100% ($3.60B) from $3.60B (in 2023) to $0.00 (in 2024).
  • Juvederm Collection revenue decreased -100% ($1.38B) from $1.38B (in 2023) to $0.00 (in 2024).
  • Linzess/Constella revenue decreased -100% ($1.11B) from $1.11B (in 2023) to $0.00 (in 2024).
  • Lumigan/Ganfort revenue decreased -100% ($432.00M) from $432.00M (in 2023) to $0.00 (in 2024).
  • MAVYRET revenue decreased -100% ($1.43B) from $1.43B (in 2023) to $0.00 (in 2024).
  • Other Aesthetics revenue decreased -100% ($1.23B) from $1.23B (in 2023) to $0.00 (in 2024).
  • Other Eye Care revenue decreased -100% ($803.00M) from $803.00M (in 2023) to $0.00 (in 2024).
  • Other Neuroscience revenue decreased -100% ($276.00M) from $276.00M (in 2023) to $0.00 (in 2024).
  • Other Products revenue decreased -100% ($3.04B) from $3.04B (in 2023) to $0.00 (in 2024).
  • Ozurdex revenue decreased -100% ($472.00M) from $472.00M (in 2023) to $0.00 (in 2024).
  • Qulipta revenue decreased -100% ($408.00M) from $408.00M (in 2023) to $0.00 (in 2024).
  • Restasis revenue decreased -100% ($436.00M) from $436.00M (in 2023) to $0.00 (in 2024).
  • RINVOQ revenue decreased -100% ($3.97B) from $3.97B (in 2023) to $0.00 (in 2024).
  • SKYRIZI revenue decreased -100% ($7.76B) from $7.76B (in 2023) to $0.00 (in 2024).
  • Ubrelvy revenue decreased -100% ($815.00M) from $815.00M (in 2023) to $0.00 (in 2024).
  • VENCLEXTA revenue decreased -100% ($2.29B) from $2.29B (in 2023) to $0.00 (in 2024).
  • Vraylar revenue decreased -100% ($2.76B) from $2.76B (in 2023) to $0.00 (in 2024).
    • Continue reading...

    Summary Table

    Products & Services 2022
    Value Change
    		2023
    Value Change
    		2024
    Value Change
    Alphagan/Combigan $346.00M - $272.00M
    21.39%
    		- -
    Botox Cosmetic $2.62B - $2.68B
    2.56%
    		- -
    Botox Therapeutic $2.72B - $2.99B
    10.00%
    		- -
    Duodopa $458.00M - $468.00M
    2.18%
    		- -
    H U M I R A $21.24B - $14.40B
    32.17%
    		- -
    Imbruvica $4.57B - $3.60B
    21.28%
    		- -
    Juvederm Collection $1.43B - $1.38B
    3.50%
    		- -
    Linzess/Constella $1.04B - $1.11B
    7.05%
    		- -
    Lumigan/Ganfort $514.00M - $432.00M
    15.95%
    		- -
    MAVYRET $1.54B - $1.43B
    7.20%
    		- -
    Other Aesthetics $1.29B - $1.23B
    4.34%
    		- -
    Other Eye Care $1.18B - $803.00M
    31.66%
    		- -
    Other Neuroscience $475.00M - $276.00M
    41.89%
    		- -
    Other Products $4.14B - $3.04B
    26.64%
    		- -
    Ozurdex - - $472.00M - - -
    Qulipta - - $408.00M - - -
    Restasis $666.00M - $436.00M
    34.53%
    		- -
    RINVOQ $2.52B - $3.97B
    57.38%
    		- -
    SKYRIZI $5.17B - $7.76B
    50.30%
    		- -
    Ubrelvy - - $815.00M - - -
    VENCLEXTA $2.01B - $2.29B
    13.89%
    		- -
    Vraylar $2.04B - $2.76B
    35.38%
    		- -
    Total Revenue $55.94B - $53.02B
    5.22%
    		-
    100.00%

    Related company

    Related